ABBV
Another turn of the Crohn’s playbook
AbbVie isn’t waiting around for the next growth engine to magically appear. It just submitted an FDA application for SKYRIZI (risankizumab-rzaa) as a subcutaneous induction option for adults with moderately to severely active Crohn’s disease.
That matters because SKYRIZI is already approved for IV induction in this setting. So this isn’t a brand-new drug story — it’s more like AbbVie asking for a new delivery lane. Same road trip, fewer pit stops.
Why investors should care
Crohn’s is a big, stubborn market, and every additional formulation can make a drug easier to prescribe and use. If the FDA says yes, AbbVie gets:
- a broader treatment option for patients and doctors,
- a potential boost to SKYRIZI’s adoption,
- and another brick in its immunology fortress.
This also keeps the narrative around AbbVie’s post-Humira future pretty lively. The company has been leaning hard on newer immune drugs to carry the load, and each incremental label expansion helps prove that plan isn’t just corporate optimism in a blazer.
The fine print, but make it useful
The filing is supported by data from the Phase 3 AFFIRM study, so this is a real regulatory step — not just AbbVie tossing a press release into the wind. Still, it’s a submission, not an approval, so the market gets the classic biotech suspense trailer instead of the full movie.
Big picture: AbbVie is trying to squeeze more mileage out of SKYRIZI, and in pharma, that’s often where the real value gets built.